Filing summary
Filing/entity and period: The supplied filing is Helius Medical Technologies, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2016, covering the six months ended September 30, 2016. This corresponds to fiscal Q2 2017 for a March 31 year-end. It does not match the request metadata naming Solana Co and 2016 Q2.
Business context: Helius is a pre-revenue medical-technology company developing the PoNS device for neurological rehabilitation. The filing reports in U.S. dollars.
Financial performance and position
- Revenue: None in the three- or six-month periods ended September 30, 2016 or 2015. Management reported limited prototype-device sales in prior periods as other income, not revenue.
- Expenses and loss: For the six months ended September 30, 2016, operating expenses were $5.49 million (general and administrative $3.49 million; R&D $2.00 million), and net loss was $6.07 million, or $0.07 per share. For the quarter, operating expenses were $3.39 million and net loss was $2.99 million.
- Year-over-year change: Six-month operating expenses rose $1.78 million from 2015, primarily from increased staffing, stock-based compensation, and clinical-trial activity. The six-month net loss widened from $0.77 million; a $2.41 million derivative fair-value gain in 2015 became a $1.02 million loss in 2016. These derivative remeasurements are noncash.
- Margins: Not meaningful because the company had no revenue.
- Cash flow: Six-month operating cash use was $4.09 million, versus $3.39 million in 2015. Financing provided $7.89 million, mainly from an offering and exercises of warrants/options. Cash increased $3.53 million to $6.17 million; investing cash flow was zero.
- Liquidity and debt: At September 30, 2016, current assets were $6.80 million, current liabilities $4.46 million, and working capital $2.34 million. The balance sheet reports no conventional borrowings; a prior $200,000 promissory note was repaid in October 2015. Derivative liabilities totaled $3.01 million and are fair-value liabilities, not cash obligations as described by management.
- Equity: Class A shares outstanding increased to 84.53 million from 72.19 million at March 31, 2016, reflecting financing and exercises. Stockholders’ equity was $2.34 million, versus a $16,192 deficit at March 31.
Outlook, risks, and unusual items
- Funding and going concern: Management said continued losses and cash outflows are expected and disclosed substantial doubt about the company’s ability to continue as a going concern. It expects to use cash on hand and seek additional equity or debt financing; there is no assurance funding will be available on acceptable terms. Management said resources were not sufficient to complete the conditions needed to generate revenue.
- Commercialization milestones: Revenue depends on clinical-trial progress, FDA clearance for the intended TBI use, commercially viable manufacturing, and customer demand. The filing gives no specific financial guidance or assurance on timing.
- Clinical/manufacturing issue: The company found 2% of battery inventory visually out of specification, briefly suspended trials to replace batteries at sites, and warned that trial and FDA-submission timelines could change. In September, the device was recommended for ISO 13485 certification, an identified regulatory milestone.
- Contingency: Under an asset purchase agreement, failure to obtain FDA clearance or make the device available for U.S. Government purchase by December 31, 2017 could trigger a $2.0 million penalty, subject to an exception. The company assessed the likelihood of payment as remote.
- Financial reporting and controls: Management concluded disclosure controls were ineffective because accounting staff lacked sufficient technical expertise for complex U.S. GAAP matters. It engaged outside assistance and added experienced personnel. The filing also describes a prior-period stock-compensation accounting revision; management said it was not material to previously issued interim statements, while noting the unrevised accounting could have materially misstated fiscal 2016 results.
- Other valuation risk: Derivative liabilities are Level 3 fair-value estimates using assumptions including share-price volatility and expected term, so reported earnings can move substantially without corresponding cash effects.
Key facts for investors to verify
- Confirm the filing is for Helius Medical Technologies, not Solana Co, and that the intended period is the quarter ended September 30, 2016.
- Assess cash runway against the $4.09 million six-month operating cash outflow and the company’s stated need for additional capital.
- Check clinical-trial progress, FDA-submission timing, battery remediation, and manufacturing readiness.
- Review the derivative-liability valuation and the potential dilution from outstanding shares, options, and warrants.
- Track remediation of ineffective disclosure controls and any further revisions to prior-period financial statements.